Last reviewed · How we verify
TDV New Formulation
At a glance
| Generic name | TDV New Formulation |
|---|---|
| Sponsor | Takeda |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults (PHASE3)
- A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDV New Formulation CI brief — competitive landscape report
- TDV New Formulation updates RSS · CI watch RSS
- Takeda portfolio CI